Brokerages Expect Dynavax Technologies Co. (NASDAQ: DVAX) Will Post Quarterly Sales of $ 146.70 Million


Wall Street brokerages expect Dynavax Technologies Co. (NASDAQ: TWOGet Rating) to post $ 146.70 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Dynavax Technologies’ earnings. The highest sales estimate is $ 146.72 million and the lowest is $ 146.68 million. Dynavax Technologies reported sales of $ 52.77 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 178%. The firm is scheduled to announce its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Dynavax Technologies will report full-year sales of $ 653.10 million for the current year, with estimates ranging from $ 649.50 million to $ 656.69 million. For the next financial year, analysts forecast that the company will report sales of $ 298.76 million, with estimates ranging from $ 136.40 million to $ 461.12 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that provide coverage for Dynavax Technologies.

Dynavax Technologies (NASDAQ: TWOGet Rating) last released its earnings results on Thursday, May 5th. The biopharmaceutical company reported $ 0.22 EPS for the quarter, missing the consensus estimate of $ 0.24 by ($ 0.02). Dynavax Technologies had a net margin of 23.12% and a return on equity of 87.36%. The business had revenue of $ 113.99 million for the quarter, compared to the consensus estimate of $ 117.76 million. During the same period in the prior year, the business posted $ 0.01 EPS.

Several equities research analysts have weighed in on DVAX shares. The Street raised shares of Dynavax Technologies from a “d +” rating to a “c” rating in a research report on Wednesday, March 30th. StockNews.com cut shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Thursday, May 12th. Finally, Zacks Investment Research cut shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, March 1st. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $ 21.00.

DVAX stock opened at $ 12.12 on Friday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.85 and a current ratio of 2.02. Dynavax Technologies has a 52 week low of $ 7.26 and a 52 week high of $ 21.39. The firm’s fifty day moving average is $ 10.32 and its 200 day moving average is $ 12.16. The firm has a market cap of $ 1.53 billion, a P / E ratio of 22.04 and a beta of 1.41.

In related news, insider Justin Burgess sold 6,000 shares of Dynavax Technologies stock in a transaction dated Tuesday, May 17th. The shares were sold at an average price of $ 10.00, for a total transaction of $ 60,000.00. Following the completion of the transaction, the insider now directly owns 3,854 shares of the company’s stock, valued at approximately $ 38,540. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 9.31% of the company’s stock.

Large investors have recently added to or reduced their stakes in the business. Advisors Asset Management Inc. increased its stake in Dynavax Technologies by 498.0% during the 1st quarter. Advisors Asset Management Inc. now owns 2,362 shares of the biopharmaceutical company’s stock valued at $ 26,000 after purchasing an additional 1,967 shares in the last quarter. Quantbot Technologies LP grew its stake in shares of Dynavax Technologies by 940.7% in the first quarter. Quantbot Technologies LP now owns 2,508 shares of the company’s biopharmaceutical stock worth $ 27,000 after acquiring an additional 2,267 shares during the period. Signaturefd LLC grew its stake in shares of Dynavax Technologies by 12,690.7% in the first quarter. Signaturefd LLC now owns 5,500 shares of the company’s biopharmaceutical stock worth $ 60,000 after acquiring an additional 5,457 shares during the period. Rockefeller Capital Management LP bought a new stake in shares of Dynavax Technologies in the third quarter worth approximately $ 163,000. Finally, Maverick Capital Ltd. bought a new stake in shares of Dynavax Technologies in the third quarter worth approximately $ 176,000. Institutional investors and hedge funds own 76.80% of the company’s stock.

About Dynavax Technologies (Get Rating)

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for the prevention of infection caused by all known subtypes of hepatitis B virus in the age of 18 years and older in the United States and Europe.

Read More

Get a free copy of the Zacks research report on Dynavax Technologies (DVAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dynavax Technologies (NASDAQ: DVAX)



Receive News & Ratings for Dynavax Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analyzes’ ratings for Dynavax Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Comment